Bank sees increasing likelihood of third Novo Nordisk upgrade
In a new memo, Citi bank concludes that there is a good chance that Novo Nordisk will upgrade its financial guidance again in November, based on sales of obesity drug Wegovy.
by marketwire, translated by catherine brett
US-based bank Citi assesses that it is increasingly likely that Novo Nordisk will upgrade its financial guidance for the third time this year in connection with its Q3 report, which will be released at the start of November.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings considers sale of Xellia Pharmaceuticals
For subscribers
.jpg&w=384&q=75)
